Scheidell J, Chueng T, Ciraldo K, Hervera B, Dakoulas S, Mahachi M
Harm Reduct J. 2024; 21(1):198.
PMID: 39543633
PMC: 11566571.
DOI: 10.1186/s12954-024-01116-5.
Plesons M, Soto Sugar S, Chimbaru R, McDonald G, Friedman L, Thompson Jr E
BMC Health Serv Res. 2024; 24(1):1260.
PMID: 39427164
PMC: 11490171.
DOI: 10.1186/s12913-024-11691-9.
Castry M, Tin Y, Feder N, Lewis N, Chatterjee A, Rudorf M
J Subst Use Addict Treat. 2024; 167:209517.
PMID: 39299504
PMC: 11527578.
DOI: 10.1016/j.josat.2024.209517.
Goodman-Meza D, Shoptaw S, Hanscom B, Smith L, Andrew P, Kuo I
Trials. 2024; 25(1):124.
PMID: 38360750
PMC: 10870682.
DOI: 10.1186/s13063-023-07899-5.
Peddireddy S, Livingston 3rd M, Young A, Freeman P, Ibragimov U, Komro K
J Subst Use Addict Treat. 2023; 159:209262.
PMID: 38103835
PMC: 10947911.
DOI: 10.1016/j.josat.2023.209262.
Opioids exacerbate inflammation in people with well-controlled HIV.
Dang C, Nelson C, Feaster D, Kizhner A, Forrest D, Nakamura N
Front Immunol. 2023; 14:1277491.
PMID: 38022645
PMC: 10646416.
DOI: 10.3389/fimmu.2023.1277491.
Racial disparities in use of syringe service programs in King County, WA: a comparison of two cross-sectional surveys.
Salow K, Jack H, Tinsley J, Banta-Green C, Kingston S, Iles-Shih M
Harm Reduct J. 2023; 20(1):133.
PMID: 37704989
PMC: 10500904.
DOI: 10.1186/s12954-023-00868-w.
HIV risk and prevention among clients of a delivery-based harm reduction service during an HIV outbreak among people who use drugs in northern rural Minnesota, USA.
Palayew A, Knudtson K, Purchase S, Clark S, Possehl L, Healy E
Harm Reduct J. 2023; 20(1):102.
PMID: 37533085
PMC: 10394878.
DOI: 10.1186/s12954-023-00839-1.
Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
Suarez Jr E, Bartholomew T, Plesons M, Ciraldo K, Ostrer L, Serota D
Ann Med. 2023; 55(1):733-743.
PMID: 36856571
PMC: 9980015.
DOI: 10.1080/07853890.2023.2182908.
"We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
Bartholomew T, Andraka-Cristou B, Totaram R, Harris S, Doblecki-Lewis S, Ostrer L
Harm Reduct J. 2022; 19(1):133.
PMID: 36463183
PMC: 9719627.
DOI: 10.1186/s12954-022-00721-6.
"They don't go by the law around here": law enforcement interactions after the legalization of syringe services programs in North Carolina.
Morrissey B, Hughes T, Ostrach B, Wilson L, Getty R, Combs T
Harm Reduct J. 2022; 19(1):106.
PMID: 36163255
PMC: 9513969.
DOI: 10.1186/s12954-022-00690-w.
Responding to a surge in overdose deaths: perspectives from US syringe services programs.
Frost M, Austin E, Corcorran M, Briggs E, Behrends C, Juarez A
Harm Reduct J. 2022; 19(1):79.
PMID: 35854351
PMC: 9295104.
DOI: 10.1186/s12954-022-00664-y.
Injection and Sexual Behavior Profiles among People Who Inject Drugs in Miami, Florida.
Chueng T, Tookes H, McLaughlin M, Arcaro-Vinas A, Serota D, Bartholomew T
Subst Use Misuse. 2022; 57(9):1374-1382.
PMID: 35686722
PMC: 9413019.
DOI: 10.1080/10826084.2022.2083171.
Implementation and first-year operating costs of an academic medical center-based syringe services program.
Bartholomew T, Patel H, McCollister K, Feaster D, Tookes H
Harm Reduct J. 2021; 18(1):116.
PMID: 34798887
PMC: 8602990.
DOI: 10.1186/s12954-021-00563-8.
Correlates of injection-related wounds and skin infections amongst persons who inject drugs and use a syringe service programme: A single center study.
Cahn B, Bartholomew T, Patel H, Pastar I, Tookes H, Lev-Tov H
Int Wound J. 2021; 18(5):701-707.
PMID: 33586860
PMC: 8450795.
DOI: 10.1111/iwj.13572.
Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis.
Bartholomew T, Tookes H, Serota D, Behrends C, Forrest D, Feaster D
Int J Drug Policy. 2020; 84:102875.
PMID: 32731112
PMC: 8814936.
DOI: 10.1016/j.drugpo.2020.102875.
Sociodemographic, Ecological, and Spatiotemporal Factors Associated with Human Immunodeficiency Virus Drug Resistance in Florida: A Retrospective Analysis.
Rich S, Poschman K, Hu H, Mavian C, Cook R, Salemi M
J Infect Dis. 2020; 223(5):866-875.
PMID: 32644119
PMC: 7938178.
DOI: 10.1093/infdis/jiaa413.
The University of Miami Infectious Disease Elimination Act Syringe Services Program: A Blueprint for Student Advocacy, Education, and Innovation.
Tookes H, Bartholomew T, St Onge J, Ford H
Acad Med. 2020; 96(2):213-217.
PMID: 32590466
PMC: 7834906.
DOI: 10.1097/ACM.0000000000003557.
When is an abscess more than an abscess? Syringe services programs and the harm reduction safety-net: a case report.
Castillo M, Ginoza M, Bartholomew T, Forrest D, Greven C, Serota D
Harm Reduct J. 2020; 17(1):34.
PMID: 32487084
PMC: 7268493.
DOI: 10.1186/s12954-020-00381-4.
Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
Bartholomew T, Tookes H, Bullock C, Onugha J, Forrest D, Feaster D
Int J Drug Policy. 2020; 78:102716.
PMID: 32146348
PMC: 7302981.
DOI: 10.1016/j.drugpo.2020.102716.